"uuid:ID","id","label","rationale","description","name","instanceType"
"ab3b538f-d949-45c9-b000-f7fe8e72c911","StudyDesign_1","","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","The main design for the study","Study Design 1","StudyDesign"
